Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Common Equity (2016 - 2025)

CorMedix (CRMD) has disclosed Common Equity for 14 consecutive years, with $405.3 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 378.76% to $405.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $405.3 million through Dec 2025, up 378.76% year-over-year, with the annual reading at $405.3 million for FY2025, 378.76% up from the prior year.
  • Common Equity hit $405.3 million in Q4 2025 for CorMedix, up from $374.1 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $405.3 million in Q4 2025 to a low of $46.2 million in Q2 2024.
  • Historically, Common Equity has averaged $109.0 million across 5 years, with a median of $62.8 million in 2021.
  • Biggest five-year swings in Common Equity: surged 31764174.79% in 2021 and later fell 29.43% in 2024.
  • Year by year, Common Equity stood at $62.8 million in 2021, then dropped by 12.32% to $55.1 million in 2022, then surged by 51.11% to $83.2 million in 2023, then rose by 1.75% to $84.7 million in 2024, then soared by 378.76% to $405.3 million in 2025.
  • Business Quant data shows Common Equity for CRMD at $405.3 million in Q4 2025, $374.1 million in Q3 2025, and $220.6 million in Q2 2025.